Validation of the Multiple Myeloma Symptom and Impact Questionnaire (MySIm-Q) in patients with multiple myeloma who were enrolled in the CARTITUDE-4 trial
Roberto Mina·Katja Weisel·Eva G. Katz·Erika Florendo·Nikoletta Lendvai·Hila Magen·Winfried Alsdorf·Iris Isufi·Katharine S. Gries·Carolina Lonardi·Ana Slaughter·Anne K. Mylin·William Deraedt·Hisayuki Yokoyama·André De Champlain·Octavio Costa Filho·Simon J. Harrison·Leyla Shune·Nitin Patel·Urvi A. Shah·Lionel Karlin·Jordan M. Schecter·Kai Fai Ho
The Multiple Myeloma Symptom and Impact Questionnaire (MySIm-Q) is a validated, disease-specific patient-reported outcome (PRO) instrument that measures symptoms and impacts experienced by patients with multiple myeloma (MM). We describe key measurement properties of the MySIm-Q instrument using CARTITUDE-4 data. The phase 3 CARTITUDE-4 (NCT04181827) trial compares ciltacabtagene autoleucel with standard-of-care regimens in patients with lenalidomide-refractory MM after 1–3 lines of therapy. Fol